Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s335962
Abstract: Purpose The US Food and Drug Administration has recently granted accelerated approval of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib as treatment for men with metastatic castration-resistant prostate cancer (mCRPC) associated with a deleterious germline or… read more here.
Keywords: management; rucaparib treatment; treatment; teaes ... See more keywords